+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Blepharitis - Pipeline Review, H1 2019

  • ID: 4767141
  • Drug Pipelines
  • 48 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • Quorum Innovations LLC
  • MORE
Blepharitis - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H1 2019, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

Report Highlights

This latest pipeline guide Blepharitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 4 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • Quorum Innovations LLC
  • MORE
Introduction

Report Coverage

Blepharitis - Overview

Blepharitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Blepharitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Blepharitis - Companies Involved in Therapeutics Development

Merck & Co Inc

NicOx SA

Novaliq GmbH

Quorum Innovations LLC

Blepharitis - Drug Profiles

(doxycycline + omega 3 fatty acid) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HY-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qi-402 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Blepharitis - Dormant Projects

Blepharitis - Product Development Milestones

Featured News & Press Releases

Mar 19, 2019: Nicox initiates phase 2 trial of NCX 4251 in Blepharitis

Mar 18, 2019: Nicox poster presentation at AGS 2019 Annual Meeting Discloses preclinical data for NCX 4251, a novel blepharitis therapy

Mar 12, 2019: Nicox announces presentations including drug candidate NCX 4251 at upcoming scientific conferences

Jan 29, 2019: Nicox announces U.S. FDA acceptance of Investigational New Drug Application for NCX 4251 phase 2 trial in Blepharitis

Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis

Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Blepharitis, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Blepharitis - Pipeline by Merck & Co Inc, H1 2019

Blepharitis - Pipeline by NicOx SA, H1 2019

Blepharitis - Pipeline by Novaliq GmbH, H1 2019

Blepharitis - Pipeline by Quorum Innovations LLC, H1 2019

Blepharitis - Dormant Projects, H1 2019

List of Figures

Number of Products under Development for Blepharitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • Quorum Innovations LLC
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767141
Adroll
adroll